STAINES-UPON-THAMES, United
Kingdom, May 21, 2019
/PRNewswire/ -- Mallinckrodt plc (NYSE:
MNK), a leading global specialty pharmaceutical company, announced
today the election of Carlos V.
Paya, M.D., Ph.D. to the company's Board of Directors.
Dr. Paya has 30 years of branded pharmaceutical industry, science
and medical practice experience, and joins the Mallinckrodt
Board effective tomorrow, May 22,
2019. He will serve as an independent director on the
Board's Portfolio Committee.
"Carlos brings an important blend of industry expertise and
clinical experience to our Board, including direct involvement in
drug development, innovation, commercialization and international
markets," said Angus Russell,
Chairman of the Board of Mallinckrodt. "He is a proven leader with
strong strategic, operational, clinical and leadership skills, with
a track record of delivering results in challenging and competitive
markets. I am confident that our Board and Mallinckrodt will benefit from his unique
experiences, diverse insights and strategic counsel."
Dr. Paya recently stepped down as the president, chief executive
officer and board member of Immune Design Corp., a late-stage
immunotherapy company, following its acquisition by Merck. He
previously served as president of Elan Pharmaceuticals, and spent a
number of years with Eli Lilly and Co. in discovery research,
clinical development leadership roles, most recently global leader
of the diabetes and endocrine franchise. Prior to his industry
roles, Dr. Paya spent nearly a decade at the Mayo Clinic-Rochester,
including his role as professor of medicine, immunology and
pathology, and vice dean of the clinical investigation program. He
is also a member of the board of BIO (Biotechnology Innovation
Organization), and a board member and chair of the nominating and
governance committee for Fludigm Corporation, a biotechnology tools
provider.
After receiving his medical and doctorate degrees from the
Universidad Complutense of Madrid Medical School, Dr. Paya
completed his specialty training in Internal Medicine, Infectious
Diseases and Immunology at the Mayo Graduate
School of Medicine. He was a research scientist in a
post-doctoral position at Institute Pasteur in Paris and completed the advanced management
program at the University of Chicago's
Booth School of Business.
ABOUT MALLINCKRODT
Mallinckrodt is a global business
consisting of multiple wholly owned subsidiaries that develop,
manufacture, market and distribute specialty pharmaceutical
products and therapies. The company's Specialty Brands reportable
segment's areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, nephrology,
pulmonology and ophthalmology; immunotherapy and neonatal
respiratory critical care therapies; and analgesics. Its Specialty
Generics and Amitiza reportable segment includes specialty generic
drugs, active pharmaceutical ingredients and
AMITIZA® (lubiprostone). To learn more about
Mallinckrodt, visit
www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution
of important company information, such as press releases, investor
presentations and other financial information. It also uses its
website to expedite public access to time-critical information
regarding the company in advance of or in lieu of distributing a
press release or a filing with the U.S. Securities and
Exchange Commission (SEC) disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Media
Daniel Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com
Investor Relations
Daniel J.
Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of
a Mallinckrodt company. Other brands are trademarks of
a Mallinckrodt company or their respective owners. ©
2019 Mallinckrodt. 5/19
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-announces-election-of-carlos-v-paya-md-phd-to-its-board-of-directors-300854285.html
SOURCE Mallinckrodt plc